| Oct 28 |
Sonnet stock tumbles 22% in wake of proposed offering filing
|
| Oct 10 |
Sonnet BioTherapeutics’ Strategic Deal to Develop DPN Treatment
|
| Oct 4 |
Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive Programs
|
| Sep 30 |
Sonnet BioTherapeutics Announces Launch of CEO Corner Platform
|
| Sep 25 |
Sonnet BioTherapeutics to execute 1-for-8 reverse stock split
|
| Sep 25 |
Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split
|
| Sep 4 |
Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series
|
| Aug 19 |
Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer
|
| Aug 14 |
Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
|
| Jul 24 |
Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study
|
